According to Vision Research Reports, the global cancer monoclonal antibodies market size is expected to hit around USD 159.96 billion by 2030, growing at a CAGR of 11.07% from 2022 to 2030.
According to Vision Research Reports, the global cancer monoclonal antibodies market size is expected to hit around USD 159.96 billion by 2030, growing at a CAGR of 11.07% from 2022 to 2030.
Report Highlights
- The humanized segment held the highest market share of 39.66% in 2021.
- The blood cancer segment held the highest market share of 23.4% in 2021.
- Lung cancer is expected to be the fastest-growing segment during the forecast period with the highest CAGR.
- The hospitals segment held the highest revenue share of 39.8% in 2021.
- North America dominated the cancer monoclonal antibodies market with a share of 37.7% in 2021.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/39431
The increasing prevalence of cancer, and product approvals along with a robust pipeline are the key factors augmenting the market growth. Furthermore, an increase in funding for R&D in this sector is expected to impact industrial growth. Moreover, the booming biosimilar market will further offer lucrative opportunities during the forecast period.
Non-small Cell Lung Cancer (NSCLC) is a common type of lung cancer. For patients with metastatic NSCLC, the prognosis is mostly poor, as only about 8% will live beyond 5 years after the diagnosis. Moreover, at present, there are no HER2-directed therapies approved precisely for treating HER2-mutant non-small cell lung cancer, which occurs in almost 2-4% of patients with non-squamous NSCLC. However, progress has been made over the last two years, mainly in the first-line setting, leaving a substantial unmet medical need. For instance, in April 2022, Daiichi Sankyo and AstraZeneca received acceptance of supplemental Biologics License Application (sBLA) of Enhertu in the U.S. for treating adult patients with unresectable NSCLC.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 62.2 billion |
| Revenue Forecast by 2030 | USD 159.96 billion |
| Growth rate from 2022 to 2030 | CAGR of 11.07% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Type, application, end-user, region |
| Companies Covered | F. Hoffmann-La Roche Ltd.; Bristol Myers Squibb Co.; Merck & Co.; GlaxoSmithKline plc; Johnson & Johnson; Amgen, Inc.; Novartis AG; AstraZeneca plc; Eli Lilly and Company; AbbVie |
The development of monoclonal antibodies has been great both in clinical and technical research applications over the past three years. Given their advantages of safety, specificity, and efficacy, there is now prevalent acceptance of mAbs as advanced therapeutic agents. Cancer is the most dominating and important area of medicinal application, accounting for almost 50% of all monoclonal antibodies-related R&D programs.
In addition, in June 2021, the European Commission approved Bristol Myers Squibb’s combination therapy of Yervoy and OPDIVO to treat patients for malignant pleural mesothelioma. In June 2022, Regeneron Pharmaceuticals, Inc. announced its plan to purchase Sanofi’s stake in the Sanofi and Regeneron partnership on Libtayo, providing the company with exclusive global development, manufacturing, and commercialization rights to the medicine. Furthermore, in May 2020, Gilead Sciences, Inc. and Arcus Biosciences, Inc. entered into a 10-year partnership to co-commercialize and co-develop recent and future therapeutic candidates in Arcus’s pipeline. Arcus has 10 current clinical studies of molecules in its range with three monoclonal antibodies.
As COVID-19 reached a tipping point in the U.S. and Europe during the last two weeks of March 2020, its far-reaching consequences were observed across industries and businesses, with hospitals postponing or canceling treatment procedures for cancer and halting clinical trials. This has hampered the market growth to an extent. However, as treatment procedures resumed, manufacturers observed a steady improvement in business in the second half of 2021.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39431
Type Insights
The humanized segment held the highest market share of 39.66% in 2021. Humanized monoclonal antibodies are engineered to replace the mouse-related immunogenic or epitope structures. Due to the low cost, availability, and quick production time for mouse monoclonal antibodies, the humanization of mouse monoclonal antibodies has been applied on a large scale, thereby driving the growth of the market. In addition, 50% of newly approved mAbs are humanized monoclonal antibodies.
Furthermore, innovative genetic engineering technology engaged in its production is another potential growth driver for this segment. Several humanized antibodies have now been constructed and designed, and many are at present being evaluated in clinical trials. However, the human segment is expected to be the fastest growing during the forecast period. An increase in the number of product approvals and product launches of human mAbs will positively impact the growth of the segment during the assessment years.
Application Insights
The blood cancer segment held the highest market share of 23.4% in 2021. There has been a tremendous increase in demand for hematological disorder treatments over the last three years, which has led pharmaceutical industries to develop novel medications, including cancer monoclonal antibodies. For instance, in August 2020, the FDA approved GSK’s BLENREP for treating patients with refractory or relapsed multiple myeloma.
However, lung cancer is expected to be the fastest-growing segment during the forecast period with the highest CAGR. The increasing prevalence of lung cancer will drive the product demand in near future. NSCLC is the most common type of lung cancer, and it accounts for about 85% of all lung cancer cases, with more than 2 million new cases in 2020 globally. Moreover, to cater growing burden of the disease, significant market players are implementing developmental activities that will offer growth opportunities in the near future. For instance, in June 2022, FDA accepted the application for Merck’s KEYTRUDA as an Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer after the completion of surgical resection.
End-user Insights
The hospitals segment held the highest revenue share of 39.8% in 2021. Some of the factors that can be attributed to the segmental share include the rising prevalence of cancer along with an upsurge in the number of patient hospitalizations. In addition, the availability of innovative drug therapies in hospitals drives patient preference. Furthermore, skilled professionals offering specialty treatments will drive the product demand in the hospitals.
Additionally, strategic activities by research organizations are going to generate lucrative growth opportunities during the review period. For instance, IRBM signed an agreement with The University of Texas MD Anderson Cancer Center in 2019. The contract focuses on the development of therapeutic mAbs against novel immune checkpoint targets. Similarly, in 2021, Celltrion Healthcare signed an agreement with the Brazilian Ministry of Health to supply two of its anticancer therapeutics - Truxima and Herzuma - to the market.
Regional Insights
North America dominated the cancer monoclonal antibodies market with a share of 37.7% in 2021. Strategic activities are key factors influencing the market growth. For instance, in September 2020, AbbVie and I-Mab signed a broad, international partnership agreement for the commercialization and development of lemzoparlimab, an advanced anti-CD47 monoclonal antibody discovered and developed by I-Mab for multiple cancers treatment. The partnership also allows for future collaboration on CD47-associated therapeutic agents.
Asia Pacific is estimated to be the fastest-growing region owing to increasing efforts by global firms to penetrate this emerging market to capture a higher share. An increasing number of international and national collaborations among entities, especially those in developed and developing countries, is expected to propel the market. In addition, an increase in the adoption of biosimilars in the region will further offer lucrative opportunities in the review period. For instance, in recent years, China’s biosimilar drug industry has established rapidly. By the end of 2019, the country had the maximum number of biosimilar drugs in research, with 391 biosimilar drugs in the research and development pipeline. As of December 2020, 11 biosimilar drugs had been accepted for marketing in China, comprising 6 drugs for oncology.
Key Players
- F. Hoffmann-La Roche Ltd.
- Bristol Myers Squibb Co.
- Merck & Co.
- GlaxoSmithKline plc
- Johnson & Johnson
- Amgen, Inc.
- Novartis AG
- AstraZeneca plc
- Eli Lilly and Company
- AbbVie
Market Segmentation
- By Type Outlook
- Humanized
- Human
- Chimeric
- Murine
- By Application Outlook
- Blood Cancer
- Breast Cancer
- Lung Cancer
- Melanoma
- Colorectal Cancer
- Liver Cancer
- Others
- By End-user Outlook
- Hospitals
- Research Institutes
- Others
- By Regional Outlook
- North America
-
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
Click Here to View Full Report Table of Contents
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/39431
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333